Matthew J. Barth MD

Matthew Barth

Matthew J. Barth
MD

Assistant Professor

Department of Pediatrics

Jacobs School of Medicine & Biomedical Sciences


Specialty/Research Focus

Pediatric Hematology-Oncology; Pediatrics

Contact Information
Roswell Park Comprehensive Cancer Center
Department of Pediatrics
Elm and Carlton Streets
Buffalo, NY 14263
Phone: (716) 845-2333
Fax: (716) 845-8003
mbarth@buffalo.edu


Patient Care

Looking for a doctor? This faculty member is affiliated with UBMD, the group comprised of practicing physicians who are also professors in the UB Jacobs School of Medicine and Biomedical Sciences.

View this faculty on UBMD


Professional Summary:

I am a pediatric hematologist/oncologist. I see young patients who are admitted to the John R. Oishei Children's Hospital and Roswell Park Comprehensive Cancer Center.

In addition to my clinical practice, I have a keen interest in hematological malignancies and the use of targeted therapies in their treatment. As a fellow in the lymphoma translational research laboratory at RPCI, I began investigating novel therapeutic anti-CD20 antibodies in cell-line and xenograft models of rituximab resistant B-cell non-Hodgkin lymphoma (B-NHL). Based on my initial findings with the antibody ofatumumab, the University at Buffalo granted me the Dr. Henry C. and Bertha H. Buswell Fellowship, an award for promising physician-scientists who are in the beginning stages of their careers. The award allowed me to continue my work with this novel monoclonal antibody and begin exploring why B-cell lymphoma cells become resistant to multiple therapeutic modalities, including anti-CD20 immunotherapy and traditional cytotoxic chemotherapy. For children with relapsed/refractory disease, this resistance portends a survival rate that is less than 20 percent.

Using cell-line models of resistant disease and a variety of techniques such as gene expression profiling, phosphoproteomics, phospho-flow cytometry and western blotting, I have sought to characterize aberrant signal transduction pathway activation in the setting of resistant B-NHL and the ability to target relevant pathways as a means to overcome or bypass therapeutic resistance. These efforts have led to collaborative research with several investigators throughout the country who have similar interests, e.g., the clinical investigation of the anti-CD20 monoclonal antibody rituximab in childhood B-NHL.

In addition to my basic science and translational research, I am involved in developing trials that investigate other novel therapies in the setting of relapsed/refractory disease. I am co-PI of an investigator-initiated trial studying the anti-CD20 monoclonal antibody obinutuzumab, in combination with chemotherapy, for relapsed/refractory childhood B-NHL. I am also an industry-sponsored investigator researching the role of rituximab in the treatment of de novo childhood mature B-NHL. Additionally, I serve on the study committees of ongoing clinical trials through the Children’s Oncology Group.

I often supervise residents on their research projects and periodically welcome medical students, college students and high school students to work with me in the lab—mostly as part of the RPCI summer research program.

I teach medical students, residents and fellows rotating through pediatric hematology and oncology, in outpatient clinics and at the bedside on inpatient units. Using brief impromptu lectures/discussions, I also teach these trainees about disease processes they encounter as they rotate through hematology/oncology. I also lecture the pediatric residents during the hematology/oncology portion of their didactic series. Additionally, I teach our hematology/oncology fellows, in small-group didactic lectures and in both inpatient and outpatient clinical encounters.

Education and Training:

  • Fellowship, Pediatric Hematology/Oncology, University at Buffalo (2011)
  • Residency, Pediatrics, University at Buffalo (2008)
  • Internship, Pediatrics, University at Buffalo (2006)
  • MD, Medicine, SUNY Upstate Medical University (2005)
  • BA, Chemistry, Stonehill College, cum laude (1999)
  • BS, Biology, Stonehill College, cum laude (1999)

Employment:

  • Assistant Professor, Pediatrics, University at Buffalo (2014-present)
  • Attending Physician, Hematology/Oncology, Pediatrics, Roswell Park Comprehensive Cancer Center (2011-present)
  • Attending Physician, Hematology/Oncology, UBMD Pediatrics, Oishei Children's Hospital (2011-present)
  • Research Assistant Professor, Pediatrics, University at Buffalo (2011–2014)
  • Research Assistant, Upstate Medical University, College of Medicine (2002)
  • Technical Research Assistant, Pulmonology, Channing Laboratory, Brigham and Women‘s Hospital (1999–2001)
  • Research Associate, Stonehill College (1998)
  • Research Assistant, Stonehill College (1997–1998)

Awards and Honors:

  • 6th International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma: Best Poster Abstract (2018)
  • Hem Onc Today: Next Generation Innovator (2017)
  • International Society of Paediatric Oncology: Young Investigator Award (2016)
  • 5th International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma: Outstanding Translational Biology Research (2015)
  • 11th International Conference on Malignant Lymphoma: Travel Award (2011)
  • Roswell Park Cancer Institute: Best Basic Science Fellow Research Report (2011)
  • University at Buffalo Jacobs School of Medicine and Biomedical Sciences: Thomas F. Frawley, MD Residency Research Fellowship (2011)
  • National Institutes of Health: Loan Repayment Program Award (2012-2016)

Research Expertise:

  • Hematological malignancies
  • Non-Hodgkin lymphoma
  • Pediatric lymphoma

Grants and Sponsored Research:

  • July 2013–June 2017
    Targeting the P13K/Akt Pathway in Therapy Resistant B-cell NHL
    St. Baldricks Foundation
    Role: Principal Investigator
    $445,000
  • July 2015–June 2016
    Targeted Therapy in Resistant B-NHL
    National Cancer Institute
    Role: Principal Investigator
  • September 2012–December 2015
    Targeted Therapeutic Approaches to Overcoming Resistance in Pediatric Aggressive B-NHL
    Hyundai Hope on Wheels
    Role: Principal Investigator
    $250,000
  • November 2014–October 2015
    Targeting CD30 Using Brentuximab Vedotin (SGN-35), an Anti-CD30 Antibody Drug Conjugate, in Non-Hodgkin Lymphoma
    Wildermuth Foundation
    Role: Principal Investigator
    $35,000
  • November 2013–October 2015
    Preclinical and Translational Investigation of Ibrutinib (PCI-32765) in Childhood, Adolescent and Young Adult B-Cell Non-Hodgkin Lymphoma
    Janssen Pharmaceuticals
    Role: Co-Investigator
    $30,000
  • July 2014–June 2015
    Targeted Therapies in B-NHL
    National Cancer Institute
    Role: Principal Investigator
  • July 2012–June 2014
    Novel Therapeutic Approaches in the Treatment of B-Cell Lymphoma
    National Cancer Institute
    Role: Principal Investigator
  • July 2011–June 2014
    Biological Activity of Lenalidomide and Ofatumumab in B-cell Lymphoma
    University at Buffalo: Henry C. and Bertha H. Buswell Research Fellowship
    Role: Principal Investigator
    $240,000
  • February 2012–December 2013
    Biological Activity of Histone Deacetylase Inhibitors in the Treatment of Pediatric Lymphoma
    Roswell Park Alliance Foundation
    Role: Principal Investigator
    $40,000

Journal Articles:

See all (15 more)

Books and Book Chapters:

  • Barth MJ, Hochberg J, El-Mallawany NK, Cairo MS. "Monoclonal Antibodies Targeting Hematological Malignancies". Immunotherapy for Pediatric Malignancies. 2017.

Abstracts:

  • Rodney RM, Rodic V, Barth MJ, Cairo MS, Hermiston ML. Microrna (miR)-17-92 Contributes to Therapy Resistance in Burkitt Lymphoma Cells. Blood. 2016; 128(22).
  • Tiwari A, Rolland D, Elmacken M, Ayello J, van de Ven C, Basrur V, Conlon K, Fermin D, Barth MJ, Klein C, Elenitoba-Johnson K, Lim MS, Cairo MS. Comparative Phosphoproteomics Study Between Obinutuzumab (GA101) Vs. Rituximab Against RTX Sensitive/Resistant Burkitt Lymphoma: Differentially Phosphorylated B Cell Receptor, Fc-Gamma Receptor, Phagocytosis and Natural Killer Cell-Mediated Cytotoxicity. Blood. 2015; 126(23).
  • Bhatti M, Ippolito T, Mavis C, Barth MJ. PI3K/Akt/mTOR Pathway Inhibition in Chemotherapy-Sensitive and -Resistant Models of Burkitt Lymphoma. Blood. 2015; 126(23).
  • Awasthi A, Ayello J, van de Ven C, Elmacken M, Reggio C, Barth MJ, Cairo MS. Comparative Study of Obinutuzumab (GA101) Vs. Rituximab Against CD20 rituximab-Sensitive and -Resistant Burkitt (BL) and Acute Lymphoblastic Leukemia (B-ALL): Potential Targeted Therapy in Patients with High Risk BL and Pre-B-ALL. Blood. 2014; 124(21).
  • Awasthi A, Rolland DCM, Elmacken M, Reggio C, Ayello J, van de Ven C, Basrur V, Conlon K, Fermin D, Barth MJ, Elenitoba-Johnson KSJ, Lim MS, Cairo MS. A Comparative Global Phosphoproteomics Analysis of Obinutuzumab (GA101) Versus Rituximab (RTX) Against RTX Sensitive and Resistant Burkitt Lymphoma (BL) Demonstrates Differential Phosphorylation of Signaling Pathways Proteins. Blood. 2014; 124(21).
  • Frys S, Czuczman NM, Mavis C, Rolland DCM, Lim MS, Tiwari A, Cairo MS, Miles RR, Barth MJ. Deregulation of the PI3K/Akt Signal Transduction Pathway Is Associated with the Development of Chemotherapy Resistance and Can be Effectively Targeted to Improve Chemoresponsiveness in Burkitt Lymphoma Pre-Clinical Models. Blood. 2014; 124(21).
  • Alrazzak M, Bambach BJ, Rokitka DA, Barth MJ. Hyperammonemic Encephalopathy Secondary to Pegylated Asparaginase Treated with Oral Lactulose Solution and Intravenous Sodium Benzoate/Sodium Phenylacetate. Pediatr Blood Cancer. 2014; 61(S1).
  • Chu Y, Yahr A, Ayello J, van de Ven C, Barth MJ, Czuczman MS, Cairo MS. Anti-CD20 Chimeric Antigen Receptor (CAR) Modified Expanded Natural Killer (NK) Cells Significantly Mediate Rituximab Sensitive and Resistant Burkitt Lymphoma (BL) Regression and Improve Survival in Human BL Xenografted NSG Mice. Blood. 2014; 20(2).
  • Awasthi A, Rolland D, Barth MJ, Ayello J, van de Ven C, Czuczman MS, Elenitoba-Johnson KSJ, Lim MS, Cairo MS. Global Phosphoproteomics Analysis Of Burkitt Lymphoma (BL) Demonstrates Abnormal Protein Phosphorylation In BCR, Spliceosome, mTOR and Chemokine Signaling Pathways In Rituximab Induced Resistant BL. Blood. 2013; 122(21).
  • Pais F, Barth MJ, Miles RR, Hermiston ML. Histone Deacetylase Inhibitors Enhance Cell Death in Burkitt Lymphoma Cells by Modulating Expression of the WNT/. Blood. 2013; 122(21).
  • Barth MJ, Mavis C, Czuczman NM, Frys S, Klener P, Czuczman MS, Hernandez-Ilizaliturri FJ. MLN4924, An Investigational Inhibitor Of NEDD8 Activating Enzyme (NAE), Is Active In Mantle Cell Lymphoma (MCL) Pre-Clinical Models and Enhances Rituximab Activity In Vivo. Blood. 2013; 122(21).
  • Lee S, Yin C, Ayello J, O'Connell T, van de Ven C, Muniz M, Barth MJ, Cairo MS. Exogenous Overexpression Of DLEU1 Significantly Induces Programmed Cell Death and Inhibits Cell Proliferation In Burkitt Lymphoma (BL) and Sensitizes Rituximab (RTX) Resistant BL Cells To RTX Induced Apoptosis. Blood. 2013; 122(21).
  • Pais F, Lee S, Rodic V, Barth MJ, Cairo MS, Hermiston M, Miles RR. Transcription Activator-Like Effector Nucleases (TALENs)-Mediated Deletion Of MIR17HG In Burkitt Lymphoma Cells Decreases mTOR Pathway Activity and Increases Chemosensitivity. Blood. 2013; 122(21).
  • Frys S, Skomra A, Czuczman NM, Mavis C, Rolland D, Lim M, Tiwari A, Cairo MS, Czuczman MS, Hernandez-Ilizaliturri FJ, Barth MJ. The Acquirement Of Rituximab Resistance Is Associated With De-Regulation Of The PI3K/Akt/mTOR Signaling Pathway Leading To Chemotherapy Resistance In Burkitt Lymphoma Pre-Clinical Models. Blood. 2013; 122(21).
  • Barth MJ, Goldman S, Smith L, Perkins S, Shiramizu B, Gross TG, Harrison L, Sanger W, Geyer MB, Giulino-Roth L, Cairo MS. Rituximab Pharmacokinetics in Children and Adolescents with De Novo Intermediate and Advanced Mature B-Cell Lymphoma/Leukaemia: A Children’s Oncology Group (COG) Report. J Clin Oncol. 2013; 31(Suppl).
  • Awasthi A, Ayello J, van de Ven C, Glassman D, Sabulski A, Barth MJ, Cairo MS. Obinutuzumab (GA101) Significantly Enhances Cell Death and ADCC Compared to Rituximab Against CD20+ sensitive and Rituximab Resistant B-Cell Non-Hodgkin Lymphoma (NHL) and Lymphoblastic Leukemia (BLL). Blood. 2012; 120(21).
  • Goldman S, Smith L, Anderson JR, Perkins S, Harrison L, Shiramizu B, Sanger W, Barth MJ, Cairo MS. Outcome of Advanced Stage (III/IV) Intermediate-Risk Patients with Mature B-NHL Using Rituximab Plus FAB Group B4 Chemotherapy: A Children’s Oncology Group Report. Fourth International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin’s Lymp. Br J Haematol. 2012; 159(S1).
  • Barth MJ, Goldman S, Zhi J, Smith L, Harrison L, Perkins SL, Shiramizu B, Gross T, Sanger W, Cairo MS. Safety and Pharmacokinetics of Rituximab in Combination with FAB Chemotherapy in Children and Adolescents with Stage III/IV Mature B-NHL and B-cell Leukemia +/- CNS Disease: A Children’s Oncology Group Report. Br J Haematol. 2012; 159(S1).
  • Goldman S, Hochberg J, Harrison L, Kallis M, Barth MJ, Galardy P, Miles R, Sanger W, Shiramizu B, Lim M, Perkins SL, Hermiston M, Frazer JK, Cairo MS. Reduced Burden of Oncologic Therapy in Advanced B-Cell Lymphoma (REBOOT ABLY) in Children, Adolescents and Young Adults with CD20 Mature B-Cell Lymphoma. Br J Haematol. 2012; 159(S1).
  • Awasthi A, Ayello J, van de Ven C, Glassman D, Sabulski A, Barth MJ, Cairo MS. Obinutuzumab (GA101): Exhibits Enhanced Cell Death and ADCC Compared to Rituximab in RTX Resistant and Sensitive Cell Lines Against B-Cell Non-Hodgkins Lymphoma. Br J Haematol. 2012; 159(S1).
  • Barth MJ, Pendurti G, Tsai P, Mavis C, Klener P, Czuczman MS, Hernandez-Ilizaliturri FJ. Ofatumumab (OFA) is a Novel Anti-CD20 Monoclonal Antibody (mAb) with Improved Anti-Tumor Activity In Vitro and In Vivo in Mantle Cell Lymphoma (MCL) Pre-Clinical Models. Blood. 2012; 120(21).
  • Barth MJ, Mavis C, Hernandez-Ilizaliturri FJ, Czuczman MS. MLN4924, an Investigational Small Molecule Inhibitor of NEDD8-Activating Enzyme (NAE), Inhibits NF-kB Activity and Induces G1 Cell Cycle Arrest and Apoptosis in Pre-Clinical Models of Hodgkin Lymphoma (HL). Blood. 2012; 120(21).
  • Frys S, Barth MJ, Gu J, Mavis C, Gibbs JF, Czuczman MS, Hernandez-Ilizaliturri FJ. Etinostat, a Novel Histone Deacetylase (HiDAC) Inhibitor is Active in B-Cell Lymphoma Pre-Clinical Models and Enhances the Anti-Tumor Activity of Rituximab, Chemotherapy Agents and Proteasome Inhibitors. Blood. 2012; 120(21).
  • Czuczman NM, Barth MJ, Dawar R, Mavis C, Klener P, Czuczman MS, Hernandez-Ilizaliturri FJ. Evaluation of the Anti-Tumor Activity of MLN4924 (a Novel NEDD8 Activating Enzyme Inhibitor) in Pre-Clinical Models of Rituximab Chemotherapy-Sensitive or -Resistant B-Cell Lymphoma. Blood. 2012; 120(21).
  • Miller J, Barth MJ, Mavis C, Tsai P, Klener P, Hernandez-Ilizaliturri FJ, Czuczman MS. Ublituximab (TGTX-1101), a Novel Anti-CD20 Monoclonal Antibody (mAb), Demonstrates Activity in Rituximab-Sensitive and Rituximab-Resistant B Non-Hodgkin Lymphoma (B-NHL) Pre-Clinical In Vitro and In Vivo Models. Blood. 2012; 120(21).
  • Dawar R, Barth MJ, Mavis C, Skitzki J, Czuczman MS, Klener P, Hernandez-Ilizaliturri FJ. Evaluation of MLN4924, an Investigational NEDD8-Activating Enzyme (NAE) Inhibitor, as a Novel Targeted Agent with Single-Agent Antitumor Activity in Mantle Cell Lymphoma (MCL) and Hodgkin Lymphoma Pre-Clinical Models. J Clin Oncol. 2012; 30(S15).
  • Barth MJ, Pendurti G, Mavis C, Czuczman NM, Gibbs JF, Deeb G, Czuczman MS, Hernandez-Ilizaliturri FJ. Activity of Rituximab and Ofatumumab Against Mantle Cell Lymphoma (MCL) in Vitro in MCL Cell Lines and Ex Vivo in Tumor Cells Derived From Patient Tumor Samples. Blood. 2011; 118(21).
  • Barth MJ, Hernandez-Ilizaliturri FJ, Mavis C, Tsai P, Gibbs JF, Czuczman MS. Ofatumumab, a Fully Human Monoclonal Antibody Targeting CD20, Demonstrates Activity Against and Potentiates the Anti-Tumor Activity of Chemotherapy Agents in Rituximab-Sensitive Cell Lines (RSCL), Rituximab-Resistant Cell Lines (RRCL), Lymphoma Xenograft. Blood. 2010; 116(21).
  • Barth MJ, Hernandez-Ilizaliturri FJ, Mavis C, Tsai P, Gibbs JF, Czuczman MS. Ofatumumab, a Fully Human Monoclonal Antibody Targeting CD20, Demonstrates Activity Against and Potentiates the Anti-Tumor Activity of Chemotherapy Agents In Rituximab-Sensitive Cell Lines (RSCL), Rituximab-Resistant Cell Lines (RRCL), Lymphoma Xenograft. Blood. 2010; 116(21).
  • Barth MJ, Hernandez-Ilizaliturri FJ, Mavis C, Tsai P, Gibbs JF, Czuczman MS. Activity of Ofatumumab (OFA), a Fully Human Monoclonal Antibody Targeting CD20, Against Rituximab (RTX)-Sensitive (RSCL) and Rituximab-Resistant Cell Lines (RRCL), In Vivo, and Primary Tumor Cells Derived from Patients with B-Cell Lymphoma. J Clin Oncol. 2010; 28(S15).
See all (20 more)

Professional Memberships:

  • International Society of Paediatric Oncology (2016–present)
  • American Society of Clinical Oncology (2011–present)
  • American Society of Hematology (2011–present)
  • American Society of Pediatric Hematology/Oncology (2011–present)

Presentations:

  • "2B8T2M, a Novel Fusion of ALT-803, an IL-15 Superagonist, with 4 Single-Chains of Anti-CD20 Antibody Significantly Enhanced Expanded Natural Killer Cells Cytotoxicity Against Rituximab Sensitive and Resistant" 6th International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma, Pediatric Cancer Research Foundation (2018)
  • "High miR-17-92 Expression is Associated with In Vitro Chemoresistance in Burkitt Lymphoma" 6th International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma, Pediatric Cancer Research Foundation (2018)
  • "Ibrutinib Significantly Inhibited Bruton's Tyrosine Kinase (BTK) Phosphorylation, In-Vitro Proliferation and Enhanced Overall Survival in a Preclinical Burkitt Lymphoma (BL) Model" 6th International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma, Pediatric Cancer Research Foundation (2018)
  • "Low Cardiac Toxicity Following Immunochemotherapy with Reduced Anthracycline Dosing in Children, Adolescents and Young Adults with B-Cell Non-Hodgkin Lymphoma" 6th International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma, Pediatric Cancer Research Foundation (2018)
  • "Low Level of Cerebrospinal Fluid (CSF) Rituximab (RTX) Following Intravenous Rituximab in Children, Adolescents and Young Adults (CAYA) with De Novo Mature B-Cell Non-Hodgkin Lymphoma (B-NHL)" 6th International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma, Pediatric Cancer Research Foundation (2018)
  • "Omipalisib (GSK458), a Dual Pan-PI3K/mTOR Inhibitor, Exhibits In Vitro and In Vivo Activity in Chemotherapy-Sensitive and -Resistant Models of Burkitt Lymphoma" 6th International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma, Pediatric Cancer Research Foundation (2018)
  • "Phase 2 Trial of Obinutuzumab, a Humanized, Glycoengineered Monoclonal CD 20 Antibody, in Combination with Ifosfamide, Carboplatin and Etoposide for Relapsed /Refractory Mature B-Cell Non-Hodgkin Lymphoma" 6th International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma, Pediatric Cancer Research Foundation (2018)
  • "Reduced Burden of Oncologic Therapy in Children, Adolescents and Young Adults with Good Risk (GR) CD20+ Mature B-Cell Lymphoma" 6th International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma, Pediatric Cancer Research Foundation (2018)
  • "Regulation of Cytokine Release and Anti-Tumor Effect of Anti-CD20 CAR Modified Expanded Natural Killer Cells by ALT-803, an IL-15 Superagonist" 6th International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma, Pediatric Cancer Research Foundation (2018)
  • "Chemotherapy and Biologic Agents: Novel Targeted Therapies for Non-Hodgkin's Lymphomas" Annual Meeting, American Society of Hematology, Moderating Session: Lymphoma - Pre-Clinical (2017)
  • "Pre-Clinical Development of Targeted Therapies for Double Hit (DH) Diffuse Large B-Cell Lymphoma (DLBCL)" Annual Meeting, American Society of Hematology (2017)
  • "Therapeutic Effects of a Novel Fusion of ALT-803, an IL-15 Superagonist, with 4 Single-Chains of Anti-CD20 Antibody (2B8T2M) in Combination with Expanded Natural Killer Cells Against Rituximab Sensitive and Resistant Burkitt Lymphoma (BL)" Annual Meeting, American Society of Hematology (2017)
  • "Clinical Application of Tumor Genomics in Pediatric Oncology" Pediatric Grand Rounds, Women and Children's Hospital of Buffalo (2017)
  • "Intravenous Pegaspargase - Are There More Hypersensitivity Reactions?" 48th Annual Congress, International Society of Paediatric Oncology (2016)
  • "Polatuzumab Vedotin (PV, Anti-CD79b-VC-MMAE) Significantly Increased Apoptosis/Reduced Cell Proliferation & Improved Survival Against Burkitt Lymphoma (BL) and Primary Mediastinal Large B-Cell Lymphoma (PMBL)" 48th Annual Congress, International Society of Paediatric Oncology (2016)
  • "Reduced Burden of Therapy in Intermediate Risk Mature B-Cell Non-Hodgkin Lymphoma (B-NHL): Preliminary Results of the Reduced Burden of Oncologic Therapy (REBOOT) Trial" 48th Congress, International Society of Paediatric Oncology (2016)
  • "Childhood Cancer Awareness" AM Buffalo, WKBW (2016)
  • "Ways to Improve Treatment for Certain Types of Childhood Cancer" WNY Living, WGRZ (2016)
  • "Preliminary Results of a Reduced Burden of Therapy Trial by Incorporation of Rituximab and Intrathecal Liposomal Cytarabine in Children, Adolescents and Young Adults with Intermediate and High Risk Mature B-Cell Lymphoma/Leukemia" Annual Meeting, American Society of Clinical Oncology (2016)
  • "Preliminary Results of the Reduced Burden of Oncologic Therapy (REBOOT) Trial in Children, Adolescents and Young Adults with Intermediate and High Risk Aggressive B-Cell Non-Hodgkin Lymphoma" Annual Meeting, American Society of Clinical Oncology (2016)
  • "Antibody Drug Conjugates (anti-CD79b-vc-MMAE, Polatuzumab Vedotin) Exhibit Enhanced Cell Death Targeted to CD79b+ Burkitt Lymphoma (BL) and Primary Mediastinal Large B-Cell Lymphoma (PMBL)" Annual Meeting, American Association for Cancer Research (2016)
  • "Obinutuzumab (GA101) versus Rituximab Against Rituximab-Sensitive and -Resistant Burkitt Lymphoma (BL) Differentially Phosphorylate BCR, Fc-Gamma Receptor, and Natural Killer Cell-Mediated Cytotoxicity Signaling Pathways" Annual Meeting, American Association for Cancer Research (2016)
  • "Novel Agents for B-Cell Non-Hodgkin Lymphoma" Spring Meeting, Children‘s Oncology Group, Non-Hodgkin Lymphoma Committee (2016)
  • "Enhanced In Vitro and In Vivo Targeting of Rituximab Sensitive and Resistant Burkitt Lymphomas (BL) by Anti-CD20 Chimeric Antigen Receptor (CAR) Modified Expanded Natural Killer Cells in Combination with a Histone Deacetylase Inhibitor, Romidepsin" BMT Tandem Meetings, American Society for Blood and Marrow Transplantation (2016)
  • "Anti-CD20 Chimeric Antigen Receptor Modified Expanded Natural Killer Cells have Significant Cytotoxicity Against Poor Risk CD20+ Burkitt Lymphoma In Vitro and in Xenografted NSG Mice" 5th International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma, Pediatric Cancer Research Foundation (2015)
  • "Ibrutinib Alone and in Combination with Dexamethasone Significantly Inhibits Cell Proliferation in Primary Mediastinal B-Cell Lymphoma (PMBL): Ibrutinib May Be a Potential Targeted Agent in Combination Therapy in Patients with PMBL" 5th International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma, Pediatric Cancer Research Foundation (2015)
  • "Ibrutinib Significantly Improves Survival in a Human Burkitt Lymphoma (BL) Xenograft NSG Mouse Model: Ibrutinib May Be a Potential Adjuvant Agent in the Treatment of BL" 5th International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma, Pediatric Cancer Research Foundation (2015)
  • "Incorporating Mitochondrial DNA (MTDNA) Measurement to Supplement Minimal Residual Disease (MRD) Assessment in B-NHL/Leukemia Treatment Strategies" 5th International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma, Pediatric Cancer Research Foundation (2015)
  • "MK-2206, an Akt Inhibitor, Decreases Proliferation, Induces Cell Cycle Arrest and Increases Responsiveness to Chemotherapy in Therapy-Sensitive and –Resistant Burkitt Lymphoma Cell Line Models" 5th International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma, Pediatric Cancer Research Foundation (2015)
  • "Obinutuzumab vs. Rituximab (RTX) Differentially Phosphorylate BCR, Fc-Gamma Receptor, Phagocytosis and Natural Killer Cell-Mediated Cytotoxicity Signaling Pathway Proteins in RTX Sensitive/Resistant Burkitt Lymphoma (BL)" 5th International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma, Pediatric Cancer Research Foundation (2015)
  • "Obinutuzumab vs. Rituximab Significantly Enhances Apoptosis, ADCC In-Vitro and Overall Survival In-Vivo of Rituximab Sensitive/Resistant Burkitt Lymphoma (BL)" 5th International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma, Pediatric Cancer Research Foundation (2015)
  • "Rituximab and Second Generation Monoclonal Antibodies" 5th International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma, Pediatric Cancer Research Foundation (2015)
  • "Safety and Efficacy of Intrathecal (IT) Liposomal Cytarabine (L-ARA-C) in Children, Adolescent and Young Adult (CAYA) Patients with De Novo Mature B-NHL/Leukemia (MBLL)" 5th International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma, Pediatric Cancer Research Foundation (2015)
  • "Targeting the PI3K/Akt/Mtor Pathway Improves Chemoresponsiveness in Cell Line Models of Chemotherapy Sensitive and Resistant Burkitt Lymphoma" 47th Congress, International Society of Paediatric Oncology (2015)
  • "Obinutuzumab Compared to Rituximab Significantly Enhances Cell Death, Antibody Dependent Cytotoxicity (ADCC) and Improves Overall Survival Against CD20+ Rituximab-Sensitive/-Resistant Burkitt Lymphoma (BL) and Precursor Lymphoblastic Leukemia (Pre-B-ALL)" Annual Meeting, American Association for Cancer Research (2015)
  • "Deregulation of the PI3K/Akt Signal Transduction Pathway is Associated With the Development of Chemotherapy Resistance and Can Be Effectively Targeted To Improve Chemoresponsiveness in Burkitt Lymphoma Pre-Clinical Models" Annual Meeting, American Society of Hematology, Lymphoma Biology (2014)
  • "Ibrutinib Significantly Alters Cell Proliferation and Programmed Cell Death in Burkitt Lymphoma (BL) Cell Lines: Ibrutinib May Be a Potential Adjuvant Agent in the Treatment of BL" Annual Meeting, American Society of Hematology, Lymphoma Biology (2014)
  • "Ibrutinib, a Selective and Covalent Inhibitor of the Bruton’s Tyrosine Kinase Significantly Inhibits Cell Proliferation and Induces Apoptosis in PMBL Cell Lines: Ibrutinib May Be a Future Targeted Agent in Combination Therapy in Patients with PMBL" Annual Meeting, American Society of Hematology, Lymphoma Biology (2014)
  • "Preclinical Activity of Type-II Anti-CD20 Monoclonal Antibody Obinutuzumab (GA101) Compared with Rituximab (RTX) Both in In-Vitro and Xenograft Models Against RTX Sensitive and Resistant Burkitt Lymphoma" Annual Meeting, American Society of Hematology, Lymphoma Biology (2014)
  • "Hyperammonemic Encephalopathy Secondary to Pegylated Asparaginase Treated with Oral Lactulose Solution and Intravenous Sodium Benzoate/Sodium Phenylacetate" Annual Meeting, American Society of Pediatric Hematology/Oncology (2014)
  • "Obinutuzumab (GA101) Significantly Increases Overall Survival Against CD20+ Rituximab-Sensitive and -Resistant Burkitt (BL) and Acute Lymphoblastic Leukemia (B-ALL): Potential Targeted Therapy in Patients with High Risk BL and Pre-B-ALL" Annual Meeting, American Association for Cancer Research (2014)
  • "Exogenous Overexpression of DLEU1 Significantly Induces Programmed Cell Death and Inhibits Cell Proliferation in Burkitt Lymphoma (BL) and Sensitizes Rituximab (RTX) Resistant BL Cells to RTX Induced Apoptosis" Annual Meeting, American Society of Hematology (2013)
  • "Histone Deacetylase Inhibitors Enhance Cell Death in Burkitt Lymphoma Cells by Modulating Expression of the WNT/Beta-Catenin Pathway and Survivin" Annual Meeting, American Society of Hematology (2013)
  • "MLN4924, an Investigational Inhibitor of NEDD8 Activating Enzyme (NAE), is Active in Mantle Cell Lymphoma (MCL) Pre-Clinical Models and Enhances Rituximab Activity In Vivo" Annual Meeting, American Society of Hematology (2013)
  • "Transcription Activator-Like Effector Nucleases (TALENs)-Mediated Deletion of MIR17HG in Burkitt Lymphoma Cells Decreases mTOR Pathway Activity and Increases Chemosensitivity" Annual Meeting, American Society of Hematology (2013)
  • "Blastic Plasmacytoid Dendritic Cell Neoplasm: A Pediatric Case Report with Review of the Literature" Annual Meeting, American Society for Clinical Pathology (2013)
  • "Rituximab Pharmacokinetics in Children and Adolescents with De Novo Intermediate and Advanced Mature B-Cell Lymphoma/Leukaemia: A Children’s Oncology Group (COG) Report" Annual Meeting, American Society of Clinical Oncology (2013)
  • "Etinostat, a Novel Histone Deacetylase (HiDAC) Inhibitor is Active in B-Cell Lymphoma Pre-Clinical Models and Enhances the Anti-Tumor Activity of Rituximab, Chemotherapy Agents and Proteasome Inhibitors" Annual Meeting, American Society of Hematology (2012)
  • "Evaluation of the Anti-Tumor Activity of MLN4924 (a Novel NEDD8 Activating Enzyme Inhibitor) in Pre-Clinical Models of Rituximab Chemotherapy-Sensitive or -Resistant B-Cell Lymphoma" Annual Meeting, American Society of Hematology (2012)
  • "MLN4924, an Investigational Small Molecule Inhibitor of NEDD8-Activating Enzyme (NAE), Inhibits NF-kB Activity and Induces G1 Cell Cycle Arrest and Apoptosis in Pre-Clinical Models of Hodgkin Lymphoma (HL)" Annual Meeting, American Society of Hematology (2012)
  • "Ofatumumab (OFA) is a Novel Anti-CD20 Monoclonal Antibody (mAb) with Improved Anti-Tumor Activity In Vitro and In Vivo in Mantle Cell Lymphoma (MCL) Pre-Clinical Models" Annual Meeting, American Society of Hematology (2012)
  • "Ublituximab (TGTX-1101), a Novel Anti-CD20 Monoclonal Antibody (mAb), Demonstrates Activity in Rituximab-Sensitive and Rituximab-Resistant B Non-Hodgkin Lymphoma (B-NHL) Pre-Clinical In Vitro and In Vivo Models" Annual Meeting, American Society of Hematology (2012)
  • "Obinutuzumab (GA101): Exhibits Enhanced Cell Death and ADCC Compared to Rituximab in RTX Resistant and Sensitive Cell Lines Against B-Cell Non-Hodgkins Lymphoma" 4th International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin‘s Lymphoma, Pediatric Cancer Research Foundation (2012)
  • "Outcome of Advanced Stage (III/IV) Intermediate-Risk Patients with Mature B-NHL Using Rituximab Plus FAB Group B4 Chemotherapy: A Children‘s Oncology Group Report" 4th International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin‘s Lymphoma, Pediatric Cancer Research Foundation (2012)
  • "Reduced Burden of Oncologic Therapy in Advanced B-Cell Lymphoma (REBOOT ABLY) in Children, Adolescents and Young Adults with CD20+ Mature B-Cell Lymphoma" 4th International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin‘s Lymphoma, Pediatric Cancer Research Foundation (2012)
  • "Safety and Pharmacokinetics of Rituximab in Combination with FAB Chemotherapy in Children and Adolescents with Stage III/IV Mature B-NHL and B-cell Leukemia +/- CNS Disease: A Children‘s Oncology Group Report" 4th International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin‘s Lymphoma, Pediatric Cancer Research Foundation (2012)
  • "Evaluation of MLN4924, an Investigational NEDD8-Activating Enzyme (NAE) Inhibitor, as a Novel Targeted Agent with Single-Agent Antitumor Activity in Mantle Cell Lymphoma (MCL) and Hodgkin Lymphoma Pre-Clinical Models" Annual Meeting, American Society of Clinical Oncology (2012)
  • "Activity of Rituximab (RIT) and Ofatumumab (OFA) Against Mantle Cell Lymphoma (MCL) In Vitro in MCL Cell Lines by Complement Dependent Cytotoxicity and Antibody Dependent Cell Mediated Cytotoxicity" Internal Medicine 2012, American College of Physicians Internal Medicine (2012)
  • "Activity of Rituximab and Ofatumumab Against Mantle Cell Lymphoma (MCL) In Vitro in MCL Cell Lines and Ex Vivo in Tumor Cells Derived from Patient Tumor Samples" Annual Meeting, American Society of Hematology (2011)
  • "Targeting CD20 in the Treatment of B-Cell Lymphoma: Rituximab and Beyond" , New York Medical College (2011)
  • "Safety and Pharmacokinetics (PK) of Rituximab (R) in Combination with FAB Chemotherapy in Children and Adolescents (C+A) with Stage III/IV Mature B-NHL: A Children‘s Oncology Group Report" 11th International Conference on Malignant Lymphoma (ICML), European Society for Medical Oncology and Japanese Society of Medical Oncology (2011)
  • "Ofatumumab, a Fully Human Monoclonal Antibody Targeting CD20, Demonstrates Activity Against and Potentiates the Anti-Tumor Activity of Chemotherapy Agents in Rituximab-Sensitive Cell Lines, Rituximab-Resistant Cell Lines, Lymphoma Xenografts" Annual Meeting, American Society of Hematology (2010)
  • "Activity of Ofatumumab (OFA), a Fully Human Monoclonal Antibody Targeting CD20, Against Rituximab (RTX)-Sensitive (RSCL) and Rituximab-Resistant Cell Lines (RRCL), In Vivo, and Primary Tumor Cells Derived from Patients with B-Cell Lymphoma" Annual Meeting, American Society of Clinical Oncology (2010)
  • "Central Venous Line Related Deep Venous Thrombosis in Pediatric Patients" Pediatric Grand Rounds, Women and Children's Hospital of Buffalo (2009)
  • "Genomewide Linkage Analysis of Quantitative Spirometric Phenotypes in Severe Early-Onset COPD" International Conference, American Thoracic Society (2002)
  • "B2 Adrenergic Receptor Polymorphisms are Not Associated with Rate of Lung Function Decline in a Population-Based Study of Men" International Conference, American Thoracic Society (2001)
  • "Family-Based Association Analysis of ARG130GLN IL-13 Polymorphism in the Childhood Asthma Management Program" International Conference, American Thoracic Society (2001)
  • "Family-Based Association Analysis of B2AR-16 Polymorphism in the Childhood Asthma Management Program" International Conference, American Thoracic Society (2001)
See all (58 more)

Service Activities:

  • UBMD Pediatrics; Board of Directors (2016–2017)
  • Pediatric Blood and Cancer; Reviewer (2016–present)
  • Pediatric Hematology and Oncology; Reviewer (2016–present)
  • Roswell Park Comprehensive Cancer Center: Scientific Review Committee; Committee Member (2016–present)
  • University at Buffalo Jacobs School of Medicine and Biomedical Sciences: Faculty Practice Management Plan; Department Representative (2015–2018)
  • Journal of Pediatrics; Reviewer (2015–present)
  • University at Buffalo Jacobs School of Medicine and Biomedical Sciences: Faculty Council; Member (2014–2018)
  • St. Baldrick's Foundation: Research Grant; Grant Reviewer (2014–2015)
  • Annals of Hematology and Oncology; Editorial Board Member (2014–present)
  • PLOS One; Reviewer (2014–present)
  • University at Buffalo: Faculty Senate; Member (2013–2015)
  • Women and Children's Hospital of Buffalo: Utilization Review Committee; Committee Member (2013)
  • Leukemia and Lymphoma; Reviewer (2013–present)
  • Children‘s Oncology Group: Young Investigator Mentoring Program (Mitchell Cairo, MD); Student Mentor (2012–2015)
  • Children‘s Oncology Group: Non-Hodgkin Lymphoma Committee; Committee Member (2011–present)
  • Children‘s Oncology Group: Study Committee; Committee Member (2011–present)

School News:

In the Media:


Clinical Specialties:

Clinical Offices:

Insurance Accepted:



Contact Information

Roswell Park Comprehensive Cancer Center
Department of Pediatrics
Elm and Carlton Streets
Buffalo, NY 14263
Phone: (716) 845-2333
Fax: (716) 845-8003
mbarth@buffalo.edu

Looking for a doctor? This faculty member is affiliated with UBMD, the group comprised of practicing physicians who are also professors in the UB Jacobs School of Medicine and Biomedical Sciences.

View this faculty on UBMD